Physician profile
Alan Feldman
NPI 1427195114
$16,192.31
in general payments reported to CMS, 2019-2025
60 companies · $2,370 in 2025
The $2,370 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,435 · 2020: $1,972 · 2021: $2,756 · 2022: $2,092 · 2023: $2,403 · 2024: $2,165 · 2025: $2,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,928 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,927.96 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,918.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,410.86 | 2019-2025 | |
| Lilly USA, LLC | $1,093.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $885.80 | 2019-2023 | Farxiga |
| Amgen INC. | $860.91 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $749.60 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $631.34 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.07 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Radius Health, INC. | $538.16 | 2019-2025 | Tymlos |
| Medtronic, INC. | $455.89 | 2021-2024 | Minimed 780g |
| Tandem Diabetes Care, INC. | $439.90 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $432.65 | 2019-2025 | |
| Insulet Corporation | $390.22 | 2021-2024 | Omnipod |
| Amarin Pharma, INC. | $378.15 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $369.78 | 2020-2025 | Recorlev, Gvoke Hypopen |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.